Emirates Drug Establishment (EDE) has approved Foundayo (orforglipron), an innovative oral treatment for chronic weight management, making the UAE the second country in the world to register the medication, developed by global pharmaceutical company Eli Lilly.
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems.
